Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its price objective decreased by investment analysts at Canaccord Genuity Group from $62.00 to $60.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 68.26% from the company’s current price.
A number of other research analysts have also weighed in on the company. Guggenheim raised their price objective on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. UBS Group increased their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday. Finally, Barclays boosted their price target on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.73.
Check Out Our Latest Stock Report on Celldex Therapeutics
Celldex Therapeutics Price Performance
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, research analysts anticipate that Celldex Therapeutics will post -4.36 EPS for the current fiscal year.
Institutional Trading of Celldex Therapeutics
Several large investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new stake in Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its holdings in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP purchased a new position in shares of Celldex Therapeutics during the 3rd quarter worth $63,000. Kestra Advisory Services LLC acquired a new position in shares of Celldex Therapeutics during the 4th quarter valued at about $98,000. Finally, Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 2nd quarter valued at about $125,000.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Read More
- Five stocks we like better than Celldex Therapeutics
- Archer and Anduril Put ACHR Stock on a New Defense Flight Path
- PayPal Rejected a $53 Billion Takeover Bid: Is the Stock Undervalued?
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
